Houston Methodist has developed the first personalized mRNA cancer vaccine designed to prevent recurrence of osteosarcoma, a rare and aggressive type of bone cancer, with the treatment made possible through a compassionate use allowance from the U.S. Food and Drug Administration (FDA).
This first-of-its-kind treatment represents a major step in personalized medicine and cancer care, using messenger RNA (mRNA) technology to instruct the patient’s immune system to target tumor-specific proteins.
Read Also: Osteoporosis could increase mortality risk in postmenopausal women
Osteosarcoma has a recurrence rate of up to 40% and 5-year survival estimates are only 20–30% following relapse, making this breakthrough a significant development in cancer treatment.
According to Houston Methodist oncologist Dr. Kai Sun, “Safety is our priority with this first-of-its-kind vaccine, which is being administered at low doses.”
The patient is tolerating the treatment very well, and Dr. Sun noted that they are already observing promising immune responses in blood biomarkers even after the first dose.
Personalized Approach
The vaccine was custom-built to target newly formed abnormal proteins unique to the patient’s cancer, with the goal of preventing its recurrence.
This approach could transform cancer care, according to Dr. John Cooke, medical director for the Houston Methodist Center for RNA Therapeutics.
Dr. Cooke led the multidisciplinary team responsible for the development of the treatment, which was completed within Houston Methodist’s facilities in just four months’ time.
Scalability and Future Applications
The treatment leveraged existing studies of similar methods that could eventually prevent the recurrence of triple-negative breast cancer.
In time, the researchers hope the treatment will be scalable so that medical centers around the world can personalize vaccines to treat other tumor-based cancers.
Jimmy Gollihar, head of the Houston Methodist Antibody Discovery & Accelerated Protein Therapeutics Laboratory and chief translational science officer, noted that “What we’re doing for cancer now builds on what we’ve spent the last four years developing for infectious diseases—working to create effective vaccine candidates in an accelerated time frame.”
The vaccine design wasn’t a single best guess that was rushed forward, but rather multiple candidates were designed, synthesized, and tested in human cells first, before moving forward with RNA synthesis.
The project exemplifies Houston Methodist’s commitment to innovation and collaboration, with a multidisciplinary team harnessing the institution’s research and clinical capabilities to create a treatment tailored to both the patient and the biology of their cancer.
Conclusion of Initial Human Trial
A personalized mRNA vaccine targeting patient-specific tumor neoantigens was developed and administered to prevent osteosarcoma recurrence, demonstrating safety and early immune activation in the initial human recipient.
This approach leverages mRNA technology to induce immune responses against unique cancer proteins, potentially offering a scalable strategy for preventing relapse in aggressive cancers.
As the first hospital system to leverage its infrastructure and expertise to develop and deliver this highly personalized therapy, Houston Methodist is paving the way for future cancer treatments.
Leave a Reply